Form 4: Lyell Immunopharma Director Brawley Otis W Reports Transaction

Director Brawley Otis W reports acquiring 35,640 shares of Lyell Immunopharma, Inc. common stock at $0.56 per share on March 31, 2025.

Summary

• On March 31, 2025, Brawley Otis W, a director of Lyell Immunopharma, Inc., acquired 35,640 shares of common stock.
• The shares were purchased at a price of $0.56 per share.
• Following the transaction, Brawley Otis W directly owns 35,640 shares of Lyell Immunopharma, Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of a transaction. The director's purchase could be seen as slightly positive, but without more context, it's difficult to assess the overall impact.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Lyell Immunopharma, Brawley Otis W, Director, Stock Acquisition, Form 4, Beneficial Ownership, LYEL